New Stock News | De Shi Biotech Plans to List on the Hong Kong Stock Exchange, China Securities Regulatory Commission Requires Explanation of Arrangements or Measures for Personal Information Protection and Data Security Before and After Listing.

On August 8, the China Securities Regulatory Commission announced the "Supplementary Materials Requirements for Overseas Issuance and Listing Registration (August 1, 2025 - August 7, 2025)". The CSRC issued supplementary material requirements for 17 companies including DeShi Bioscience. Among them, the CSRC requires DeShi Bioscience to explain arrangements or measures for personal information protection and data security before and after listing. It is reported that DeShi Bioscience submitted an IPO application to the main board of the Hong Kong Stock Exchange on June 29, 2025, with Huatai International as the exclusive sponsor. The CSRC asked DeShi Bioscience to provide supplementary explanations on the following issues, and requested lawyers to verify and provide clear legal opinions: 1. Based on the main business situation described in the filing materials, please explain if the company and its subsidiaries' actual business involves "human stem cells, gene diagnosis and treatment technology development and application" or other areas with foreign investment access restrictions or prohibitions, and provide related judgment basis. Confirm whether the company continues to meet the requirements of foreign investment access policies before and after this issuance and listing. 2. Please explain if the company and its subsidiaries are involved in the development and operation of websites, mini-programs, apps, public accounts, etc., and whether they provide information content to third parties. Specify the types of information content provided, information content security protection measures, the scale of collected and stored user information, data collection and usage, arrangements or measures for personal information protection and data security before and after listing. 3. Please explain whether the shares held by the shareholders participating in this "full circulation" have any issues such as pledge, freezing, or other defects in rights. According to the prospectus, based on Frost & Sullivan data, DeShi Bioscience's independently developed iMedImageTM is the world's largest general medical image base model in terms of parameter scale, which has been successfully commercialized and recognized as the world's first commercially available cross-modal medical image base model. DeShi Bioscience has always focused on the medical imaging AI industry. The company's proprietary iMedImageTM has a cross-modal pre-training architecture that allows a single unified model to support 19 medical imaging modalities (such as chromosome, CT, MRI, ultrasound, and pathology), covering over 90% of clinical medical imaging scenarios, including reproductive health, blood system malignant tumors, and radiation health. With its unified basic capabilities, strong generalization ability, and extendable architecture tools, iMedImageTM drives AI solutions for multi-modal, multi-task, and multi-scenario applications. These solutions significantly reduce research and development costs and time to market, address uneven distribution of medical resources, improve diagnostic efficiency, and provide an innovative path for scalable intelligent medical care and health.